肝癌早期诊断标志物的研究新进展

doi:10.20047/j.issn1673-7210.2023.01.08

摘要
图/表
参考文献(34)
相关文章 (15)

全文: PDF (576 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肝细胞癌是我国发病率和死亡率最高的恶性肿瘤之一，给社会造成了严重的负担。肝脏的超声检查和肿瘤标志物甲胎蛋白（AFP）是目前世界范围内应用最广泛的检查措施。然而，超声和AFP在早期肝癌的检测中，准确性有限。目前，许多研究都在寻找诊断早期肝癌的可靠生物标志物，这样的生物标志物将有助于早期肝癌的诊断，确保早发现、早诊断、早治疗。本文总结了蛋白类标志物、基因类标志物（非编码RNA和DNA甲基化）作为生物标志物在鉴别早期肝癌中的作用，并讨论了他们作为诊断早期肝癌生物标志物的潜在意义。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈文亮徐细明

关键词 ：肝癌, 早期诊断, 蛋白标志物, 非编码RNA, DNA甲基化

Abstract：Hepatocellular carcinoma is one of the malignant tumors with the highest morbidity and mortality in our country, which poses a serious burden to society. Liver ultrasound and tumor marker alphafetoprotein (AFP) are the most widely used tests in the world. However, ultrasound and AFP have limited accuracy in the detection of early liver cancer. At present, many studies are looking for reliable biomarkers for the diagnosis of early liver cancer. Such biomarkers will help in the diagnosis of early liver cancer and ensure early detection, diagnosis, and treatment. This review summarizes the role of protein markers, gene markers (non-coding RNA and DNA methylation) as biomarkers in the identification of early liver cancer, and discuss their potential significance as biomarkers in the diagnosis of early liver cancer.

Key words： Liver cancer Early diagnosis Protein biomarker Non-coding RNA DNA methylation

基金资助:国家自然科学基金资助项目（31971166）。

通讯作者: 徐细明（1976.8-），男，博士，主任医师，博士生导师；研究方向：消化系统肿瘤。

作者简介: 陈文亮（1993.12-），男，武汉大学第一临床学院2020级肿瘤学在读硕士研究生；研究方向：消化系统肿瘤。

引用本文:

陈文亮徐细明. 肝癌早期诊断标志物的研究新进展[J]. 中国医药导报, 2023, 20(1): 40-44.
CHEN Wenliang XU Ximing. New progress in the study of markers for the early diagnosis of liver cancer. 中国医药导报, 2023, 20(1): 40-44.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.01.08 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I1/40

[1] Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Liu D，Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China [J]. Biosci Trends，2021，15（3）：142-147.
[3] Pi?觡ero F，Dirchwolf M，Pess?觝a MG. Biomarkers in Hepatocellular Carcinoma：Diagnosis，Prognosis and Treatment Response Assessment [J]. Cells，2020，9（6）：1370.
[4] Chang TS，Wu YC，Tung SY，et al. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis [J]. Am J Gastroenterol，2015，110（6）：836-844.
[5] Becker-Assmann J，Fard-Aghaie MH，Kantas A，et al. Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma [J]. Chirurg，2020，91（9）：769- 777.
[6] Zhang YS，Chu JH，Cui SX，et al. Des-γ-carboxy prothrombin （DCP） as a potential autologous growth factor for the development of hepatocellular carcinoma [J]. Cell Physiol Biochem，2014，34（3）：903-915.
[7] Poté N，Cauchy F，Albuquerque M，et al. Performance of PIVKA-Ⅱ for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion [J]. J Hepatol，2015，62（4）：848-854.
[8] Peng F，Yuan H，Zhou YF，et al. Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist Ⅱ，Alpha-Fetoprotein，and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma [J]. Int J Gen Med，2022，15：5763-5773.
[9] Shen Q，Fan J，Yang XR，et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma：a large-scale，multicentre study [J]. Lancet Oncol，2012，13（8）：817-826.
[10] Kim SY，Lee HS，Bang SM，et al. Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma [J]. Cancers （Basel），2021，13（8）：1828.
[11] Han EK，Tahir SK，Cherian SP，et al. Modulation of paclitaxel resistance by annexin Ⅳ in human cancer cell lines [J]. Br J Cancer，2000，83（1）：83-88.
[12] Liu YY，Ge C，Tian H，et al. The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma [J]. Am J Cancer Res，2017，7（6）：1285-1297.
[13] Saad ZM，Fouad Y，Ali LH，et al. Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma [J]. Asian Pac J Cancer Prev，2020， 21（9）：2661-2665.
[14] Zhou F，Shang W，Yu X，et al. Glypican-3：A promising biomarker for hepatocellular carcinoma diagnosis and treatment [J]. Med Res Rev，2018，38（2）：741-767.
[15] Bakheet AMH，Zhao C，Chen JN，et al. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope techology [J]. Hepatol Int，2020，14（1）：96-104.
[16] Jia X，Liu J，Gao Y，et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma：a systematic review with meta-analysis [J]. Arch Med Res，2014，45（7）：580-588.
[17] Wu M，Liu Z，Li X，et al. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma [J]. Onco Targets Ther，2020，13：827-840.
[18] Guo Y，Liu B，Huang T，et al. HOTAIR modulates hepatocellular carcinoma progression by activating FUT8/core-fucosylated Hsp90/MUC1/STAT3 feedback loop via JAK1/ STAT3 cascade [J]. Dig Liver Dis，2022，S1590-8658（22）00255-9.
[19] Wei W，Liu M，Ning S，et al. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma [J]. BMC Cancer，2020，20（1）：6.
[20] Fu Y，Xu X，Huang D，et al. Plasma Heat Shock Protein 90 alpha as a Biomarker for the Diagnosis of Liver Cancer：An Official，Large-scale，and Multicenter Clinical Trial [J]. EBio Medicine，2017，24：56-63.
[21] Huang Z，Zhou JK，Peng Y，et al. The role of long noncoding RNAs in hepatocellular carcinoma [J]. Mol Cancer，2020，19（1）：77.
[22] Kim SS，Baek GO，Ahn HR，et al. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma [J]. Mol Oncol，2020，14（10）：2646-2659.
[23] Kim SS，Baek GO，Son JA，et al. Early detection of hepatocellular carcinoma via liquid biopsy：panel of small extracellular vesicle-derived long noncoding RNAs identified as markers [J]. Mol Oncol，2021，15（10）：2715-2731.
[24] Zhang H，Ding R，Chen D. Value of miR-21 levels as potential biomarkers in the early diagnosis of hepatocellular carcinoma：a meta-analysis [J]. Biomarkers，2021，26（7）：586-597.
[25] Lin XJ，Chong Y，Guo ZW，et al. A serum microRNA classifier for early detection of hepatocellular carcinoma：a multicentre，retrospective，longitudinal biomarker identification study with a nested case-control study [J]. Lancet Oncol，2015，16（7）：804-815.
[26] Zang J，Lu D，Xu A. The interaction of circRNAs and RNA binding proteins：An important part of circRNA maintenance and function [J]. J Neurosci Res，2020，98（1）：87-97.
[27] Dong ZR，Ke AW，Li T，et al. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity [J]. Mol Cancer，2021，20（1）：75.
[28] Liang WC，Wong CW，Liang PP，et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway [J]. Genome Biol，2019，20（1）：84.
[29] Wei Y，Chen X，Liang C，et al. A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma [J]. Hepatology，2020，71（1）：130-147.
[30] Yu J，Ding WB，Wang MC，et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma：A large-scale，multicenter study [J]. Int J Cancer，2020，146（6）：1754-1763.
[31] Zhang L，Lu Q，Chang C. Epigenetics in Health and Disease [J]. Adv Exp Med Biol，2020，1253：3-55.
[32] Zhang YJ，Wu HC，Shen J，et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA [J]. Clin Cancer Res，2007，13（8）：2378-2384.
[33] Kisiel JB，Dukek BA，Kanipakam RVSR，et al. Hepatocellular Carcinoma Detection by Plasma Methylated DNA：Discovery，Phase Ⅰ Pilot，and Phase Ⅱ Clinical Validation [J]. Hepatology，2019，69（3）：1180-1192.
[34] Cai J，Chen L，Zhang Z，et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma [J]. Gut，2019，68（12）：2195-2205.